data from electronic medical records can be used to provide population-based evidence for cardiovascular risk management decisions and to evaluate treatment effectiveness in real-life clinical conditions. 12 The aim of the present study was to analyze the effectiveness of statins in a general population according to their coronary risk estimation.
RESULTS
Between July 2006 and December 2007, 617,850 individuals fulfilled all inclusion criteria and 20,799 (3.3%) initiated statin therapy. Losses to follow-up were 3.1% (n 5 19,557), all of them due to transfer out of the Information System for the Development of Research in Primary Care (SIDIAP Q ) database. Median follow-up was 7.7 years (ranging from 7.2, 1st quartile, to 8.0, 3rd quartile). There were 523,580 participants with 10-year coronary heart disease (CHD) risk <5% (84.7%), 53,534 with risk 5-7.4% (8.6%), 21,824 with risk 7.5-9.9% (3.5%), and 18,912 with risk 10-19.9% (3.0%). The percentage of individuals with complete follow-up was: 91.05% (CHD category <5%), 84.41% (5-7.4%), 80.27% (7.5-9.9%), and 75.37% (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) .9%).
The study flowchart is detailed in Figure 1 . The missing data for incomplete variables and a comparison of the complete-case and imputed datasets are shown in Supplementary Table S1 . Mean values of these variables were lower after multiple imputations, as expected.
Baseline characteristics
Women constituted 53.8% of the sample. Mean age was 50.4 (SD 10.5) years. Diabetes was present in 4.9% of participants, hypertension in 17.38%, smoking in 34.8%, and dyslipidemia in 15.2%. The proportion of adherent new users (6-month medical possession ratio (MPR) 70%) was 54.9%; median MPR was 76.6% (1st quartile, 46.0; 3rd quartile, 100). Descriptive analysis of the number of days covered by statins is shown in Table S2 .
Main baseline characteristics of patients with high (MPR 70%) and low (MPR <70%) statin adherence and of nonusers are shown in Table 1 , stratified by CHD risk before propensity score (PS) adjustment. Main baseline characteristics after PS adjustment are shown in Table 2 . No clinically relevant standardized differences were observed after adjusting for PS. Other baseline characteristics before and after PS adjustment are shown in Tables S3, S4 , respectively. Over 80% of new users were treated with a statin of moderate LDL-reduction capacity (Table S4) . Baseline characteristics after PS adjustment are also shown for the complete dataset in Table S5 .
Outcomes and statin effectiveness
For 2006-2014, overall unadjusted incidences per 1,000 personyears at risk (PYAR) of atherosclerotic cardiovascular disease (ASCVD), CHD, ischemic (IS), and all-cause mortality were 2.98 (95% confidence interval (CI) 2.93-3.03), 2.60 (95% CI 2.55-2.64), 1.75 (95% CI 1.71-1.79), and 3.44 (95% CI 3.39-3.49), respectively. Unadjusted incidences and adjusted hazard ratios (HRs) for all outcomes are shown by CHD risk categories in Table 3 . Statins showed a protective effect in individuals with MPR 70% for ASCVD across all risk groups, and this effect was significant in the risk groups defined from 7.5% through 9.9% and 10-19.9%; however, individuals with MPR <70% in any CHD risk category showed a lower and nonsignificant effect size reduction in ASCVD.
Statins protected individuals with MPR 70% from CHD in the two risk groups defined from 5-9.9% and in the 10-19.9% risk group; however, individuals with MPR <70% showed no clinically relevant reduction in CHD in any risk category.
Furthermore, no significant differences in IS were found in any risk category, regardless of MPR. All-cause mortality reduction was statistically significant only in individuals with MPR 70% and 10-19.9% risk (0.73 (0.59-0.91)). Variables not balanced between statins users and nonusers were further included in the models but the results did not change (data not shown). Standard adjusted models showed similar results (Table S6) .
Overall, 5-year number needed to treat (NNT) was lower at higher levels of risk, ranging from 470 in the group with lowest CHD risk to 62 in the highest risk group.
Adverse events
There was no significant increase in cancer and hemorrhagic stroke attributable to statins, regardless of CHD risk category. However, diabetes increased in all CHD risk categories, although this was a nonsignificant trend in the 7.5-9.9% risk group (Table 4) . Standard adjusted models showed similar results (Table S7) . Tables S8 and S9 show statin effectiveness and adverse effects in the complete dataset. The results of the proportional hazards assumption was met for all outcomes except for diabetes in the <5% category (Table S10) . VOLUME 104 NUMBER 4 | October 2018 | www.cpt-journal.com 720
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DISCUSSION
This observational retrospective study aimed at estimating statin effectiveness according to CHD risk levels in a general population without previous cardiovascular disease. We found that statin treatment was effective in preventing ASCVD across the range of coronary risk in people with high adherence to therapy (MPR >70%). Specifically, statin therapy decreased ASCVD risk by 30% and 26% in individuals with cardiovascular risk of 7.5- 9.9% and 10-19.9%, respectively. Treatment with statins also decreased all-cause mortality by 27% in those at highest risk (10-19.9% category). We found no clinically relevant effect size of statin treatment in people with low adherence to therapy (MPR <70%), irrespective of their CHD risk. Our finding that statins effectively reduced ASCVD in individuals with 10-year CHD risk 10-19.9% who adhered to treatment is consistent with clinical trials and systematic reviews aimed at evaluating statin efficacy in primary prevention 6, 7 and in line with recent guidelines. [1] [2] [3] [4] In addition, our estimate of 62 as the 5-year NNT to prevent one ASCVD event in the 10-19.9% risk category was similar to the results of the Cholesterol Trialists Collaborators' meta-analysis in primary prevention, which included individuals with 10-year coronary risk of about 15%, similar to the individuals in our 10-19.9% category. 6 Hence, statin therapy may be useful in this CHD risk category.
We found that statin treatment effectively reduced relative risk in the 7.5-9.9% category, similar to that of the cited metaanalysis with a pooled population comparable to ours in this 10-year risk category. 5 Although our 5-year NNT estimate in this risk category was about 20% higher compared to the 10-19.9% category (75 vs. 62), most individuals with an estimated CHD risk 7.5-9.9% could benefit from statin treatment, in line with US guidelines.
1,2 Additional research is needed to define strategies that improve the predictive ability of risk functions by considering new risk factors 13 and/or by individualized consideration of LDL cholesterol levels or response to treatment. 14, 15 Patient management strategies must take into account the net benefit of absolute risk reduction, 10, 14 long-term treatment safety, costs, and patient preference 9, 16 in the 10-19.9% and 7.5-9.9% categories.
The relative benefit for protection against ASCVD in the 5-7.4% risk category in individuals with MPR 70% was mainly due to the protective effect for CHD. This finding is in accordance with the results of a recent pragmatic clinical trial in an intermediate-risk population, defined as a 10-year cardiovascular risk of about 10% but 10-year CHD risk of about 5%. 7 However, the net benefit of statin treatment in the <5% and 5-7.4% categories could be limited because of the large 5-year NNT to prevent one event (470 and 204, respectively).
In our study, the magnitude of the statin effectiveness in preventing IS was similar to that of clinical trials and metaanalyses. 6, 17 It is likely that the few IS events contributed to the lack of statistical significance in our results. However, the lack of significant association between statin treatment and IS was in line with previous observational data. 18 There is also great debate about the effectiveness of statins on all-cause mortality, 6, 7, 19, 20 despite agreement that the relative risk reduction is moderate ($10%). Our findings were consistent with this effect size in all risk categories except for the association between statins and all-cause mortality in individuals with MPR 70% and 10-19.9% risk. The effect was greater than expected. We cannot dismiss the possibility of residual healthy-user effect, although this was not observed in other risk categories.
About 46% of new users had a 6-month MPR <70%. Importantly, patients with poor adherence are more likely to have a higher incidence of cardiovascular and cerebrovascular events and all-cause mortality than adherent patients. 21 Hence, a first-line strategy to improve statin effectiveness in primary care should be the implementation of interventions to improve adherence.
Adverse effects
Statin treatment in users with MPR 70% increased the risk of diabetes from 15% to 32% depending on risk category, consistent with results from clinical trials. 22 This excess risk should be considered in recommendations for lifetime statin therapy. We observed no increased risk of cancer or hemorrhagic stroke among new users of statins, which is also consistent with the literature. 23 ,24 A major strength of this study is that it was based on highquality, internally validated electronic medical records that provided a large sample size, ensured high external validity, 12 and reflected real-life clinical conditions by including individuals often excluded from clinical trials (e.g., women, diabetics, people with inflammatory immune disorders).
Ten-year coronary risk was stratified by an equation validated in Spain. 25 The concordance between the estimated and observed 10-year coronary risk in our study reinforces the quality of this risk equation.
We acknowledge several limitations. First, residual confounding is a possibility, especially indication bias 26 ; we excluded frail individuals and used a new users design to minimize confounding factors and then adjusted for PS in each coronary risk stratum. The exclusion of frail individuals may also lead to an unrepresentative sample; however, the population of greatest interest consists of individuals more likely to receive statins in primary prevention and frail individuals are less likely to initiate statin treatment. The inclusion of prevalent users may also lead to a sample whose covariates at baseline, especially lipid profile, could be affected by previous statin use.
Second, missing data can influence results. To avoid this type of selection bias, where the population with missing data somehow differs from those with complete data, we imputed the missing values for continuous variables instead of excluding those records. Overall, the population with complete data was more likely to be older, female, hypertensive, and diabetic (Supplementary file, Table S4 ). The percentage of missing data ranged from 28-79%. The appropriateness of performing multiple imputations depends not only on the percentage and mechanism of missing values but on the number of complete observations used in the imputation process. In our study, 77,894 complete cases were available to impute variables with missing values, increasing the likelihood of representing the general population.
Third, we could not analyze the effect of statins on cardiovascular death, as cause-of-death is not available in the SIDIAP Q database. Fourth, we cannot exclude some underreporting of outcomes, which could lead to nondifferential misclassification and reduce statistical power, biasing results towards the null hypothesis. There were too few cases to accurately estimate the effect of statins use on acute liver disease and myopathy incidence or on relative and absolute risk reduction.
In addition, follow-up was shorter than the 10-year CHD risk; that may result in a misclassification of individuals in each CHD risk category in the long term. We also estimated 10-year CHD incidence based on the observed data using a Weibull model, which showed that the 10-year mean incidence of CHD in each risk category matched the Framingham score estimates SDiff: standardized differences respect to nonusers.
( Table S11) . Low data quality could also generate misclassification. In this study the presence of cardiovascular risk factors and outcomes were previously validated in SIDIAP. 27 Moreover, the validity of statins exposure in the medical records was confirmed by the official invoicing records from community pharmacies.
Lastly, we could not analyze statin effectiveness in subgroups based on statin dose or sex because of the few events in the highdose category and among women in the highest coronary risk categories.
In conclusion, statin treatment in adherent patients was associated with a reduction in ASCVD risk ranging from 16-30%. The 5-year NNT in the 5-7.4% and 7.5-9.9% CHD risk categories was higher (204 and 75, respectively) than in the 10-19.9% CHD risk category (5-year NNT: 62). Statins were less effective in preventing IS, compared to CHD. All-cause mortality was significant only in the 10-19.9% CHD risk category (HR: 0.73 (0.59-0.91)). Our results indicate that interventions in primary care should focus on improving adherence to statin therapy. Statin treatment should remain a priority in managing patients at high 10-year CHD risk (10-19.9% ). In the same way, most patients in the 7.5-9.9% category could benefit from statin treatment, although the increased risk of diabetes, costs, and patient preference must be taken into account. In the 5-7.4% range, the higher 5-year NNT (204) raises the question of whether it is reasonable to recommend treatment in these patients.
METHODS
Study design
This was a historical population-based cohort study.
Record linkage system
The Information System for the Development of Research in Primary Care (SIDIAP) is a clinical database of anonymized longitudinal patient records for nearly six million people (80% of the Catalan population and 10.2% of the total population of Spain) registered in 274 primary care practices having a total of 3,414 general practitioners (GPs). A subset of records from GPs who surpass a predefined data quality standard constitutes the SIDIAP Q , which provides research-quality anonymized clinical data covering 14 million person-years (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . SIDIAP Q is highly representative of both urban and rural areas of Catalonia. 28 The quality of SIDIAP Q data has been previously documented, and the database has been used to study the epidemiology of a number of health outcomes. 13, 27, 29 Ethics approval was obtained from our local Ethics Committee.
Study population
All individuals aged 35 to 74 years were included in SIDIAP Q .
Inclusion criteria
Only new users (defined as receiving simvastatin, pravastatin, lovastatin, fluvastatin, rosuvastatin, or atorvastatin for the first time) were selected. For this group, the index date was defined as the first statin invoice; those same dates were then randomly assigned to nonusers to achieve a similar distribution. Individuals with at least one visit to their healthcare provider within 18 months before the index date were included.
Exclusion criteria
Frail individuals with cancer, dementia, paralysis, organ transplant, on dialysis, or institutionalized at baseline were excluded, as were patients with previous history of peripheral arterial disease, CHD, IS or hemorrhagic stroke, revascularization, heart failure or cardiac therapy (ATC code C01), or cholesterol-lowering drugs other than statins taken between July 2006 and December 2007. Individuals with <2 invoices in pharmacological records for statins during the enrollment period were also excluded. Finally, we excluded individuals with estimated CHD risk 20% (n 5 1,561) because statins are clearly cost-effective in this risk category in terms of absolute risk reduction and safety.
1-4
Statin exposure Statin exposure was calculated according to the medical possession ratio (MPR), defined as the number of days of statin supplied according to pharmaceutical records during 6 consecutive months, divided by 183 days. Statin users were categorized as low (MPR <70%) or high (MPR 70%) adherence to therapy.
Outcomes Cardiovascular diseases during follow-up were identified from SIDIAP Q codes in both primary care (ICD-10) and hospital discharge records (ICD-9). Outcomes were CHD (a composite of acute myocardial infarction (fatal and nonfatal AMI) and angina), fatal and nonfatal ischemic stroke (IS), and all-cause mortality. The primary outcome of the study was ASCVD a composite of AMI and IS. Entry of cardiovascular codes in SIDIAP Q has been previously validated. 27 Adverse effects Liver toxicity and myopathy were attributed to statins if these effects occurred within 12 months of initiating treatment. New-onset diabetes, cancer, and hemorrhagic stroke were attributed to statin exposure if the diagnosis occurred at least 1 year after the prescription date. 
Baseline covariates
The following covariates at baseline were considered: 10-year coronary risk was calculated using the 10-year CHD risk Framingham function adapted and validated in the Spanish population. 25 Local guidelines 31 recommend the use of this function, which allows the estimation of CHD risk in people without previous CVD up to the age of 74 years and includes fatal and nonfatal coronary events. Individuals were categorized to assess benefit in the low-intermediate and high-intermediate coronary risk populations, as follows: <5%, 5-7.4%, 7.5-9.9%. and 10-19.9%.
Statistical analysis
Results are expressed as percentages for categorical variables and as mean (SD), or median (quartiles) otherwise. Under the missing-at-random assumption, we used multiple imputations by chained equations 32 to replace missing baseline values for total cholesterol, high-density The study used the deprivation index derived from the multicenter MEDEA study in Spain. The index is described in detail in the Supplementary file.
lipoprotein cholesterol, triglycerides, glucose, systolic and diastolic blood pressure, BMI (weight and height), and deprivation index score. The 10-year coronary risk was calculated and individuals were then classified into the study's four coronary risk categories. The process of multiple imputation and the variables considered in the models are detailed in the Supplementary file. Because of nonrandom treatment allocation, a multinomial model based on potential confounding covariates ( Table 5) was used to calculate a PS for statin therapy (PS model development and assessment are shown in the Supplementary file). Baseline characteristics of the groups before and after adjusting for PS were compared using standardized differences. Variables with standardized differences <0.10 were considered well-balanced. Ten PS and 10 hazard ratio (HR) values were calculated for each coronary risk group in each imputed dataset. A pooled HR was then calculated according to Rubin's rules 32 with PS as covariate. Variables not balanced between statins users and nonusers were further included in the models. In a sensitivity analysis, we compared complete-case results with those of multiple imputation and standard adjusted models were also performed (Supplementary file).
Proportionality of hazards assumption was tested by calculating the median of the chi-square tests of the models fitted for the 10 imputed datasets (Supplementary file). Five-year NNT for one additional patient to survive to a specific timepoint was also calculated. Statistical analysis used R software. 33 
Ethics approval
Ethics approval was obtained from our local Ethics Committee (IDIAP Jordi Gol) and all procedures were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Additional Supporting Information may be found in the online version of this article.
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